When a patient asks whether an aesthetic device is "FDA approved," the honest answer often requires a longer conversation. Most energy-based devices used in aesthetics — lasers, radiofrequency platforms, ultrasound systems — enter the US market through the 510(k) pathway, which clears them as substantially equivalent to a previously marketed device. That is not the same as the premarket approval (PMA) process required for breast implants and some higher-risk devices. And clearance does not guarantee that a device will remain on the market without problems.
An analysis of 304 recall records extracted from the FDA device recall database — filtered to aesthetic-related product codes including breast implants (FTR), laser delivery systems (GEX), cryolipolysis devices, and injectable-related device entries — provides a data-backed picture of what has gone wrong, which manufacturers and device types are most frequently involved, and what patients should look for when evaluating whether a device in their provider's office has a clean regulatory history.
This article breaks down the recall data by device type, manufacturer, root cause, and trend over time. It also explains how FDA device recall classifications work, why the Allergan BIOCELL textured breast implant recall of 2019 dominates the dataset, and what the open (still-active) recalls mean for patients today.
How FDA device recalls are classified
The FDA classifies each recall into one of three tiers based on the probability and severity of harm:
- Class I — reasonable probability that use of the device will cause serious adverse health consequences or death.
- Class II — use of the device may cause temporary or medically reversible health consequences, or the probability of serious harm is remote.
- Class III — use of the device is not likely to cause adverse health consequences.
The recall database extract analyzed here contains product-level recall entries with recall status, root-cause descriptions, and product descriptions, but does not include the FDA's classification tier. For classification, readers can search individual recall numbers at the FDA's recall database (accessdata.fda.gov).
Total recall volume and the laser dimension
The dataset contains 304 recall records. Of these, 199 (65%) fall under product code GEX — a broad code covering laser delivery systems, fiber optics, and laser surgical instruments. These are predominantly surgical laser systems used across urology, gastroenterology, neurosurgery, and general surgery, not aesthetic-specific devices. Firms like Boston Scientific, Olympus, and American Medical Systems account for the majority.
Aesthetic-specific devices represent a distinct subset. To isolate them, we filtered for product descriptions referencing breast implants, cryolipolysis, body contouring, dermal fillers, aesthetic injectables, aesthetic lasers, microneedling, skin tightening, and related cosmetic applications. This yielded 44 aesthetic-specific recall records.
Aesthetic recalls by device type
| Device type | Recall records | Share |
|---|---|---|
| Breast implants | 24 | 55% |
| Other aesthetic devices | 8 | 18% |
| Injectable/filler devices | 5 | 11% |
| Aesthetic lasers | 3 | 7% |
| Body contouring devices | 3 | 7% |
| Cryolipolysis/fat-freezing | 1 | 2% |
Breast implants dominate the aesthetic recall profile. Of the 24 breast-implant recall records, 12 list Allergan (now part of AbbVie) as the recalling firm, with the remainder split between earlier firms that Allergan acquired (Inamed, McGhan) and entries where the firm field was blank.
The Allergan BIOCELL recall: context for the 2019 spike
The year with the highest number of aesthetic recalls in the dataset is 2019, with 14 records — and the majority are directly linked to the Allergan BIOCELL textured breast implant recall initiated on July 24, 2019.
At the FDA's request, Allergan voluntarily recalled all BIOCELL textured breast implants and tissue expanders from the global market. The recall was driven by data linking the BIOCELL macro-textured surface to breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a rare T-cell lymphoma. At the time of the recall, the FDA had identified 573 unique BIA-ALCL cases worldwide, including 33 deaths. Of those cases where the manufacturer was known, 481 were associated with Allergan breast implants, and 12 of 13 known deaths occurred in patients with Allergan implants.
The BIOCELL surface was unique to Allergan — no other manufacturer used it. Mentor and Sientra textured implants were not subject to the recall. The recall did not affect Allergan's smooth-surface or MICROCELL implants.
The FDA has stated that asymptomatic patients with BIOCELL textured implants do not need prophylactic removal, but should monitor for symptoms including persistent breast swelling, pain, lumps, or skin changes, and report any symptoms to their plastic surgeon.
Aesthetic recall trend by year
| Year | Aesthetic recalls |
|---|---|
| 2003 | 2 |
| 2005 | 4 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 3 |
| 2016 | 4 |
| 2017 | 3 |
| 2018 | 3 |
| 2019 | 14 |
| 2021 | 2 |
| 2023 | 2 |
| 2024 | 1 |
The 2019 spike is entirely attributable to the BIOCELL action. Excluding that event, aesthetic-device recalls run at a modest 2–4 per year — consistent with the FDA's overall recall volume for a specialized device category.
Top recalling firms (aesthetic-specific)
| Firm | Recall records |
|---|---|
| Allergan PLC | 13 |
| Quasar Bio-Tech | 3 |
| Inamed Corp | 3 |
| Merz Aesthetics / Merz North America | 4 |
| Cytrellis Biosystems | 2 |
| Lumenis | 2 |
| Zeltiq Aesthetics | 1 (6 total including non-aesthetic) |
| Biolase Technology | 1 |
| Ideal Implant | 1 |
Allergan's 13 recalls are all breast-implant related. Merz's four recalls involve injectable and device products across the Merz Aesthetics and Merz North America entities. Lumenis entries are for aesthetic laser products.
Root causes of aesthetic recalls
| Root cause | Count |
|---|---|
| Unknown/Undetermined by firm | 10 |
| Other | 7 |
| Error in labeling | 5 |
| Under Investigation by firm | 4 |
| Process control | 3 |
| Employee error | 2 |
| Labeling False and Misleading | 2 |
| Device Design | 2 |
| Nonconforming Material/Component | 2 |
| Packaging process control | 1 |
| Material/Component Contamination | 1 |
| No Marketing Application | 1 |
| Software design | 1 |
| Use error | 1 |
The most common cause — "Unknown/Undetermined by firm" — reflects the reality that manufacturers sometimes initiate recalls before completing root-cause analysis, particularly when the FDA requests urgent market action. The Allergan breast implant recalls dominate this category.
Labeling errors (5 entries combined) are the second-largest cluster, including incorrect expiration dates, labeling mix-ups, and false or misleading promotional claims. These are typically Class II recalls — unlikely to cause serious harm, but representing regulatory non-compliance that could mislead providers or patients.
Open (still-active) aesthetic recalls
Of the 44 aesthetic recalls, 13 remain in "Open" status — meaning the recall action has not yet been classified as completed or terminated by the FDA. Of these 13 open recalls, 7 are Allergan breast-implant entries related to the BIOCELL action and its aftermath. The remaining open recalls include entries from Merz, Lumenis, and smaller aesthetic-device firms.
An open recall does not mean the device is still being sold. The BIOCELL textured implants were withdrawn from the market in 2019. Open status indicates that the FDA's administrative process for tracking the recall — confirming that all inventory has been returned, all providers notified, and all patients accounted for — is still ongoing.
The broader laser recall picture
While aesthetic lasers represent only 3 of the 44 aesthetic-specific recalls, the broader dataset contains 144 laser-related recall records. These are predominantly surgical laser fiber-delivery systems, laser probes, and accessories from firms like Olympus (20 recalls), Boston Scientific (20), and American Medical Systems (14 combined). The root causes skew toward nonconforming materials, device design failures, and software issues.
For the aesthetic-laser market specifically, the recall volume is low but not zero. Candela (12 total laser recalls across both aesthetic and non-aesthetic products), Lumenis (11 total), and smaller Chinese manufacturers like Beijing Syntech Laser (8 recalls, all for nonconforming materials) have all had entries. The root causes range from software defects to radiation-control violations to component failures.
The 510(k) versus PMA dimension
A 2025 analysis published in Cureus (PMC11749930) reviewing FDA device approvals and recalls across surgical specialties found that devices cleared through the 510(k) pathway are 5.32 times more likely to be recalled than those that went through the PMA process. The study's surgical-device breakdown identified dermal implants for aesthetic use (product codes FTR, FWM) and powered laser surgical instruments (GEX) among the most-recalled categories for PMA and 510(k) pathways respectively.
This is relevant context for the aesthetic-device recalls in the present dataset. Breast implants — which require PMA — have had fewer individual recall events (24) relative to the number of products and years on market, but the consequences of those recalls (the BIOCELL action linked to 33 deaths worldwide) are far more severe. Laser delivery systems — which enter through 510(k) — have far more recall events (144 in the broader dataset) but typically involve component or labeling issues with lower patient-safety impact.
The regulatory pathway through which a device reaches the market is one of the strongest predictors of whether it will be recalled. Patients evaluating a device should ask not just "Is it FDA cleared?" but "Was it cleared through 510(k) or approved through PMA?" — and understand the difference in evidence requirements between the two.
What patients should take away
Breast implant recalls dominate the data, and they are concentrated at one manufacturer. The Allergan BIOCELL recall was the largest aesthetic-device recall in the dataset by a wide margin. If you have textured breast implants, ask your surgeon whether they are BIOCELL and discuss the FDA's monitoring guidance.
Aesthetic energy-device recalls are relatively rare. Lasers, RF, ultrasound, and body-contouring devices have had few recalls relative to the number of units in clinical use. When recalls do occur, they tend to involve component failures or labeling issues rather than direct patient-safety emergencies.
Check the recall database before your procedure. The FDA maintains a searchable recall database at accessdata.fda.gov. You can look up your device by product name, manufacturer, or product code. If your provider cannot tell you the manufacturer and model of the device they plan to use, that is a red flag independent of any recall history.
Recall status matters. A "Terminated" recall means the FDA has verified that the firm completed its correction or removal. An "Open" recall means the action is still being tracked. Neither status tells you about the underlying risk — but a device with multiple open recalls from different root causes deserves closer scrutiny.
The FDA's MAUDE database complements recall data. Recalls capture market-level actions (removals, corrections, notifications). The MAUDE database captures individual adverse-event reports. For a complete picture of a device's safety profile, check both.
Sources
- FDA Medical Device Recalls Database: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm
- FDA Safety Communication — Allergan Voluntarily Recalls BIOCELL Textured Breast Implants and Tissue Expanders (July 2019): https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/allergan-voluntarily-recalls-biocellr-textured-breast-implants-and-tissue-expanders
- FDA Breast Implant Postmarket Safety Information: https://www.fda.gov/medical-devices/breast-implants/breast-implant-postmarket-safety-information
- FDA Classify Your Medical Device: https://www.fda.gov/medical-devices/overview-device-regulation/classify-your-medical-device
- FDA Medical Device Safety and Recalls: https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/medical-device-recalls
- FDA MAUDE (Manufacturer and User Facility Device Experience) Database: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/search.CFM
- Review of Approvals and Recalls of US Specific Medical Devices (PMC11749930, 2025): https://pmc.ncbi.nlm.nih.gov/articles/PMC11749930
